Literature DB >> 10720961

Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease.

B Pannier1, A P Guerin, S J Marchais, F Metivier, M E Safar, G M London.   

Abstract

BACKGROUND: Cardiovascular complications are the major cause of death in end-stage renal disease (ESRD) patients. These complications are associated with concomitant cardiac and vascular remodeling, including left ventricular (LV) hypertrophy and hypertrophy of arterial walls. The endothelium influences the process of arterial remodeling. ESRD patients are characterized by the development of both cardiovascular remodeling and endothelial dysfunction.
METHODS: Common carotid artery (CCA) intima-media thickness (IMT), CCA diameter, CCA distensibility, LV mass, and function were determined in 60 stable ESRD patients on hemodialysis and 34 age-, sex-, and blood pressure (BP)-matched controls, and their relationships with endothelial alterations were estimated by forearm postischemic vasodilation [flow debt repayment (FDR)] measured by venous plethysmography. We also evaluated the relationships between FDR and several cardiovascular risk factors or markers of inflammatory response or endothelial activation, for example, duration of dialysis, BP, smoking habits, cholesterol, parathormone (PTH), serum albumin, plasma fibrinogen, C-reactive protein (CRP), plasma homocysteine, plasminogen activator inhibitor (PAI-1), and von Willebrand factor (vWF).
RESULTS: ESRD patients had increased LV mass, CCA diameter and CCA IMT, and had decreased CCA distensibility (P < 0.05). While the postischemic peak flow was comparable in controls and ESRD patients (29.2 +/- 9.1 vs. 27.9 +/- 0.2 mL/100 mL/min), FDR was lower in ESRD patients (116 +/- 31 vs. 88 +/- 32%, P < 0.001) because of the shorter duration of vasodilation (127 +/- 36 vs. 96 +/- 32 s, P < 0.001). The time to complete FDR was longer in ESRD patients (110 +/- 54 vs. 162 +/- 72 s, P < 0.001). ESRD patients had lower high-density lipoprotein cholesterol and serum albumin (P < 0.01) and higher triglycerides, fibrinogen, plasma homocysteine, vWF (P < 0.01), and PAI-1 (P < 0.05). For ESRD patients, significant negative age- and pressure-independent correlations were established between FDR and CCA diameter, duration of dialysis, and PAI-1. FDR was positively correlated with serum albumin. FDR and time to FDR were negatively correlated with CCA IMT and LV mass. CCA distensibility was positively associated with FDR (P < 0.001) and negatively with time to FDR (P < 0.001). The PAI-1 concentration was positively correlated with CCA IMT (P < 0.01) and negatively with CCA distensibility (P < 0.001).
CONCLUSIONS: Our data provide the first evidence that cardiac and arterial remodeling in ESRD patients are inversely related to forearm reactive hyperemia. The diminished hyperemic response is due to the shorter duration of hyperemia and is associated with higher concentrations of serum markers of endothelial activation, suggesting that, in ESRD patients, endothelial dysfunction may be a factor influencing cardiovascular changes.

Entities:  

Mesh:

Year:  2000        PMID: 10720961     DOI: 10.1046/j.1523-1755.2000.00936.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Nocturnal hemodialysis.

Authors:  Paramjit Kalirao; Joshua M Kaplan
Journal:  Clin Exp Nephrol       Date:  2009-01-20       Impact factor: 2.801

2.  Simultaneous extraction of carotid artery intima-media interfaces in ultrasound images: assessment of wall thickness temporal variation during the cardiac cycle.

Authors:  Guillaume Zahnd; Maciej Orkisz; André Sérusclat; Philippe Moulin; Didier Vray
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-07       Impact factor: 2.924

3.  Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease.

Authors:  Mehmet Baha Aytaç; Murat Deveci; Kenan Bek; Özlem Kayabey; Zelal Ekinci
Journal:  Pediatr Nephrol       Date:  2015-10-02       Impact factor: 3.714

4.  Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease.

Authors:  Ruth F Dubin; Isabella Guajardo; Amrita Ayer; Claire Mills; Catherine Donovan; Lauren Beussink; Rebecca Scherzer; Peter Ganz; Sanjiv J Shah
Journal:  Hypertension       Date:  2016-08-22       Impact factor: 10.190

5.  Flow-mediated vasodilation in end-stage renal disease.

Authors:  Francis H Verbeke; Bruno Pannier; Alain P Guérin; Pierre Boutouyrie; Stephane Laurent; Gérard M London
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

6.  Flow-mediated vasodilatation of the brachial artery in children with chronic kidney disease.

Authors:  Amy C Wilson; Elaine Urbina; Sandra A Witt; Betty J Glascock; Thomas R Kimball; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

Review 7.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Relations of measures of endothelial function and kidney disease: the Framingham Heart Study.

Authors:  Meredith C Foster; Michelle J Keyes; Martin G Larson; Joseph A Vita; Gary F Mitchell; James B Meigs; Ramachandran S Vasan; Emelia J Benjamin; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2008-07-09       Impact factor: 8.860

9.  Neurological disorders in a murine model of chronic renal failure.

Authors:  Jean-Marc Chillon; François Brazier; Philippe Bouquet; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

10.  Microcirculatory changes and skeletal muscle oxygenation measured at rest by non-infrared spectroscopy in patients with and without diabetes undergoing haemodialysis.

Authors:  Roberto Alberto De Blasi; Remo Luciani; Giorgio Punzo; Roberto Arcioni; Rocco Romano; Marta Boezi; Paolo Menè
Journal:  Crit Care       Date:  2009-11-30       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.